The Food and Drug Administration has agreed to decide by the end of this year whether men with advanced prostate cancer driven by faulty DNA repair genes should get a targeted pill added to standard hormone therapy from the very start of treatment, rather than waiting until the cancer stops responding.
The agency granted priority review to talazoparib, sold as Talzenna, combined with enzalutamide, sold as Xtandi, for metastatic castration-sensitive prostate cancer with alterations in homologous recombination repair genes. A decision is expected in the fourth quarter of 2026.
The combination is already approved for a later, harder stage of the disease. Moving it earlier matters because many men never make it to a second or third line of treatment. Roughly one in four men with advanced prostate cancer carry these DNA repair alterations, and their outcomes have historically been worse.
The Regulatory Step Behind the Headline
Priority review is a scheduling decision, not a verdict. It shortens the FDA's target review clock for applications the agency judges could offer a significant improvement over existing options. It does not mean approval is assured, and the agency retains full authority to reject the application or ask for more data.
Pfizer, which makes both drugs, announced the acceptance and framed the stakes in commercial and clinical terms at once. Chief oncology officer Jeff Legos said the combination "would offer patients with HRR-driven disease a new treatment option," language that comes from the company and should be read as such. The European Medicines Agency is reviewing the same expansion.
Synthetic Lethality Explained Without the Jargon
Cells repair broken DNA constantly. They have several backup systems for it. PARP is one of those systems, handling smaller single-strand breaks. Genes like BRCA1, BRCA2, ATM, and CDK12 run a different repair pathway that handles bigger damage.
When a tumor already has a broken version of that second pathway, and you block PARP with a drug, the cell loses both repair routes at once. Damage accumulates until the cell dies. Healthy cells, which still have their second pathway intact, survive. Researchers call this synthetic lethality, and the National Cancer Institute describes PARP inhibitors as drugs that block "PARP proteins from repairing damaged DNA."
That is why this treatment only makes sense for men whose tumors carry the relevant alterations. Without the underlying repair defect, there is no trap to spring.
Reading the TALAPRO-3 Numbers Honestly
The application rests on the phase 3 TALAPRO-3 trial, presented at the 2026 American Society of Clinical Oncology meeting and published simultaneously in the New England Journal of Medicine. It enrolled 599 men with metastatic prostate cancer still responding to hormone therapy, all with alterations in at least one of twelve predefined repair genes. All participants received androgen deprivation therapy plus enzalutamide, then were randomly assigned to add talazoparib or a placebo.
Adding talazoparib cut the risk of the cancer growing on scans or the patient dying by 52 percent. Median time to progression had not been reached in the combination group after about three years of follow-up, compared with 45.8 months on enzalutamide alone. Benefit appeared in both the BRCA-mutated subgroup, at 63 percent risk reduction, and the non-BRCA subgroup, at 43 percent.
That second finding is the one specialists focused on. In earlier PARP inhibitor trials, the benefit largely came from BRCA carriers, leaving everyone else in doubt. David Olmos, M.D., Ph.D., of Hospital Universitario 12 de Octubre in Spain, who served as the ASCO abstract discussant and was not part of the trial, said simply: "The trial is clearly positive." He singled out the signal in patients with ATM mutations as the most notable feature.
One caveat sits at the center of the data. Overall survival was immature at the time of analysis. There were 74 deaths in the combination group and 91 in the control group, a difference that did not reach statistical significance. Delaying progression on a scan is meaningful, but it is not the same as proving men live longer. That question is unanswered.
The Toxicity Trade That Patients Will Feel
Adding a PARP inhibitor is not free. Serious side effects, graded three or higher, occurred in 81 percent of men on the combination compared with 44 percent on enzalutamide alone. Serious adverse events were reported in 42 percent versus 32 percent. The most common problems were anemia, fatigue, and low neutrophil counts.
Anemia is the dominant issue, and it arrives early rather than building over years. Nearly one in five patients permanently stopped talazoparib because of side effects, and about 5 percent stopped specifically because of anemia. The trial protocol required dose reduction when severe anemia developed, and patient-reported quality of life was broadly similar between the two groups, apart from greater appetite loss in the talazoparib arm.
That combination of facts is what a real conversation with an oncologist should cover. Roughly doubling the rate of serious adverse events in exchange for a delay in progression, with survival data still pending, is a genuine trade rather than an obvious win.
Genetic Testing Becomes the Gatekeeper
None of this reaches a patient without a test. Men with metastatic prostate cancer need germline and tumor genetic testing to know whether they carry a qualifying alteration, and testing rates in community practice have lagged behind what guidelines recommend.
That gap has practical consequences. Men treated at large academic centers are more likely to be tested and enrolled in trials than men treated in rural or under-resourced settings. Insurance coverage for tumor sequencing varies, prior authorization is common, and results can take weeks. A newly diagnosed patient who wants this option on the table should ask about testing early rather than after first-line treatment is already underway.
Anyone currently on prostate cancer treatment should not change or stop anything based on a news report. This combination is not approved for the earlier stage discussed here, and only an oncologist reviewing an individual case can weigh it.
The bottom line: the FDA will decide by year's end whether to allow a PARP inhibitor to be added to hormone therapy earlier in advanced prostate cancer for men with DNA repair alterations. The progression data are strong, the survival data are not yet in, and the toxicity is substantial. MedicalDaily will report the FDA decision when it is issued.
Frequently Asked Questions
Is this combination available now? It is approved for metastatic castration-resistant prostate cancer with these gene alterations. It is not approved for the earlier castration-sensitive stage described here. That is what the FDA is reviewing.
Which patients would qualify if it is approved? Men with metastatic prostate cancer that still responds to hormone therapy and whose tumors carry an alteration in one of the predefined DNA repair genes, including BRCA1, BRCA2, ATM, CDK12, and CHEK2.
Does the trial show men live longer? Not yet. Survival data were immature, with 74 deaths in the combination group and 91 in the control group, a difference that was not statistically significant. Longer follow-up is needed.
What are the main side effects? Anemia, fatigue, and low neutrophil counts. Serious side effects occurred in 81 percent of the combination group compared with 44 percent on hormone therapy alone.
Do I need a genetic test? Yes. Without documented alterations in the relevant repair genes, this approach is not expected to help. Ask your oncologist about both germline and tumor testing.
When will the FDA decide? The agency set a target action date in the fourth quarter of 2026. It can approve, decline, or request additional information.
Who funded the trial? Pfizer, which manufactures both talazoparib and enzalutamide, sponsored TALAPRO-3 and submitted the application.
